Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc., based in Conshohocken, PA, disclosed on March 5, 2026, that it has granted equity awards to 20 new non-executive employees on March 1, 2026. These awards were given as equity inducement awards under Madrigal’s 2025 Inducement Plan. The granting of these equity awards was approved by Madrigal’s independent Compensation Committee in adherence to Nasdaq Listing Rule 5635(c)(4). Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biopharmaceutical company dedicated to developing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments